Epstein-Barr Virus Infection

Jennifer A. Kanakry, Richard F. Ambinder

Research output: Chapter in Book/Report/Conference proceedingChapter


Epstein-Barr virus (EBV) is a ubiquitous infection. In the setting of hematopoietic cell transplantation (HCT), EBV-associated post-transplantation lymphoproliferative disorder (EBV-PTLD) is a recognized complication. Particular approaches to graft manipulation and the prevention or treatment of graft-versus-host disease are associated with increased risk of EBV-PTLD. Other donor and host factors may also contribute to risk. In some series, the risk of EBV-PTLD has exceeded 25%, whereas in others the risk is 1% or less. In this chapter, aspects of EBV biology relevant to HCT patients are reviewed with a focus on EBV-PTLD risk factors, prevention, clinical manifestations, and treatment. The utility of EBV monitoring in the post-HCT period and evolving approaches to the treatment of EBV-associated malignancies are discussed.

Original languageEnglish (US)
Title of host publicationThomas' Hematopoietic Cell Transplantation
Subtitle of host publicationFifth Edition
Number of pages9
ISBN (Electronic)9781118416426
ISBN (Print)9781118416006
StatePublished - Jan 1 2016


  • Allogeneic hematopoietic cell transplantation
  • Epstein-Barr virus
  • Epstein-Barr virus DNA
  • Epstein-Barr virus-specific cytotoxic T-lymphocytes
  • Graft manipulation
  • Immunosuppression
  • Latent infection
  • Post-transplantation lymphoproliferative disorder
  • Rituximab
  • T-cell depletion

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Epstein-Barr Virus Infection'. Together they form a unique fingerprint.

Cite this